Publication of Research Demonstrating the Impact of ARINA-1 on Mucus Transport in Cystic Fibrosis
Renovion, Inc., a biopharmaceutical company on a mission to transform the lives of patients with chronic lung diseases characterized by mucus and inflammation, announced publication of results from research conducted at The University of Alabama Birmingham. The research was funded in part by the Cystic Fibrosis Foundation and was conducted at The Rowe Lab at The Gregory Fleming James Cystic Fibrosis Research Center. Results of the research were published in the peer-reviewed American Journal of Respiratory Cell and Molecular Biology 1. The paper provides an overview of the impact of ARINA-1 on mucus transport and shows that the ARINA-1 moves mucus significantly better than currently available options in cystic fibrosis (CF).
“These research results demonstrate the significant impact that ARINA-1 has on restoring mucus transport in primary human bronchial epithelial cells from dF508 CF patients,” said Steven M. Rowe, MD, MPSH and Director of The Gregory Fleming James CF Research Center at UAB. “Based on our studies demonstrating that ARINA-1 is more effective than hypertonic saline for mucus clearance in CF cells, the potential for ARINA-1 helping people with CF improve clinically is promising. These results support the importance of advancing the clinical program for ARINA-1 in CF patients, many of whom still have a need for mucus clearance even with the availability of novel CFTR modulators, and possibly in other chronic lung diseases characterized by excess mucus."
Adewale, et al. (2020) demonstrated that ARINA-1 significantly improves mucociliary transport (MCT) alone and with a CFTR modulator therapy in dF508 homozygous primary human bronchial epithelial cells isolated from CF patients. This activity is CFTR-independent and is driven by the mechanism of ARINA-1 in decreasing the viscosity of the mucus layer overlaying the cells, lending applicability to CF and potentially other chronic lung diseases characterized by viscous mucus.
The full paper, titled "Novel Therapy of Bicarbonate, Glutathione and Ascorbic Acid Improves Cystic Fibrosis Mucus Transport," is available online by clicking here.
1. Adewale, A. T. et al. Novel Therapy of Bicarbonate, Glutathione and Ascorbic Acid Improves Cystic Fibrosis Mucus Transport. Am. J. Respir. Cell Mol. Biol. rcmb.2019-0287OC (2020). doi:10.1165/rcmb.2019-0287OC
Renovion is a clinical stage pharmaceutical company with a nebulized therapy that restores mucus clearance and reduces inflammation in the lungs. The company is focused on developing ARINA-1 for orphan chronic inflammatory lung diseases.
About Gregory Fleming James
The UAB Gregory Fleming James Cystic Fibrosis Research Center is a university-wide interdisciplinary research center funded by the National Institutes of Health, the Cystic Fibrosis Foundation, and institutional resources dedicated to fostering an innovative, multidisciplinary environment to pursue, advance, and train in cystic fibrosis-related science. The center is led by director Steven M. Rowe, MD, MSPH.